Like other pro-inflammatory cytokines such as TNFα and IL-1β, IL-6 is an important therapeutic target of immune disorders, and anti-IL-6 receptor antibody, tocilizumab, has been developed as a therapy in human diseases, including rheumatoid arthritis (RA) and Castleman’s disease [11]. The gene discussed is TNF; the disease is rheumatoid arthritis.